After three decades and a surprise rejection, first treatment for babies born without a thymus secures FDA approval

Zachary Brennan

Senior Editor

Sumitovant Biopharma’s subsidiary Enzyvant late Friday won approval for its first treatment, which is also the first promising treatment for babies without a thymus, an …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After three decades and a surprise rejection, first treatment for babies born without a thymus secures FDA approval

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Pfizer’s prostate cancer data leak shows promising results in early-stage study

What will pharma's share buyback shopping spree mean for M&A?

Trump 2.0 blog: Wayback Machine is insufficient for US health data, judge says

Novartis returns for its anticoagulant in up to $3.1B buy of Blackstone’s Anthos

Biohaven lands priority review on second-chance application for neurodegenerative drug

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Af­ter three decades and a sur­prise re­jec­tion, first treat­ment for ba­bies born with­out a thy­mus se­cures FDA ap­proval

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

After three decades and a surprise rejection, first treatment for babies born without a thymus secures FDA approval